Vol. 149, No. 5 — January 31, 2015

GOVERNMENT NOTICES

DEPARTMENT OF HEALTH

CONTROLLED DRUGS AND SUBSTANCES ACT

Notice to interested parties — Proposed order amending Schedule II to the Controlled Drugs and Substances Act and regulations amending the Schedule to the Narcotic Control Regulations with respect to synthetic cannabinoids

This notice provides interested stakeholders with the opportunity to provide comments on Health Canada’s intent to pursue amendments to Schedule II to the Controlled Drugs and Substances Act (CDSA) and to the Schedule to the Narcotic Control Regulations (NCR) to make more explicit the controlled status of synthetic cannabinoids in order to facilitate efforts to protect the health and safety of Canadians from the risks posed by the trafficking and abuse of these substances.

Synthetic cannabinoids are a rapidly emerging class of new psychoactive substances. These substances are often mixed with dried plant materials, marketed under a variety of brand names and labelled as “legal alternatives” to cannabis. Some synthetic cannabinoids possess pharmacological properties similar to those of tetrahydrocannabinol (THC), the major psychoactive component of cannabis. Such psychoactive activity is the result of these synthetic cannabinoids binding to and activating cannabinoid receptors in the brain, referred to as their agonist effects. The chemical structures of these synthetic cannabinoids can be either similar or unrelated to that of THC.

Since the initial detection of psychoactive synthetic cannabinoids in herbal blends in 2004, such products have achieved widespread distribution worldwide, thereby creating significant risks to health and safety. Globally, close to 400 such synthetic cannabinoids have been identified thus far, which are developed and manufactured for illicit purposes.

These synthetic cannabinoids are not controlled under the United Nations Convention on Psychotropic Substances, 1971 to which Canada is a signatory. Nevertheless, some of these synthetic cannabinoids are controlled under national legislation in countries such as the United Kingdom, Ireland, New Zealand and the United States.

In Canada, the CDSA and its regulations provide a legislative framework for the control of substances that can alter mental processes and that may present a risk to public health and safety when diverted or misused. Currently, the heading of Item 1 of Schedule II to the CDSA and Item 17 of the Schedule to the NCR captures “Cannabis, its preparations, derivatives and similar synthetic preparations.” While synthetic cannabinoids are not expressly listed in these schedules, these substances are controlled under the term “similar synthetic preparations.”

Nevertheless, considering the growing importance of psychoactive synthetic cannabinoids in illicit drug production, Health Canada has determined that further specificity with respect to these synthetic cannabinoids in Schedule II to the CDSA and the Schedule to the NCR would facilitate the administration and enforcement of the CDSA and its regulations.

Health Canada is proposing to amend Schedule II to the CDSA and the Schedule to the NCR by replacing the terms “similar synthetic preparations” by a new entry that would specify that these synthetic cannabinoids, as well as their salts, derivatives and isomers, should read as cannabinoid receptor type I agonists. In the interest of clarity, a list of specific classes of known core chemical structures of these synthetic cannabinoids would also be included.

The publication of this notice in the Canada Gazette, Part I, initiates a 30-day comment period. If you are interested in this process or have comments on this notice, please contact the Regulatory Policy Division, Office of Policy and Strategic Planning, Controlled Substances and Tobacco Directorate, Healthy Environments and Consumer Safety Branch, Health Canada by mail at Address Locator 0302A, 150 Tunney’s Pasture Driveway, Ottawa, Ontario K1A 0K9, or by email at ocs_regulatorypolicy-bsc_ politiquereglementaire@hc-sc.gc.ca.

January 16, 2015

JACQUELINE GONÇALVEZ
Director General
Controlled Substances and Tobacco Directorate
Healthy Environments and Consumer Safety Branch

[5-1-o]

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Decisions, undertakings and orders on claims for exemption

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer of the Workplace Hazardous Materials Bureau hereby gives notice of the decisions of the screening officer, respecting each claim for exemption and the relevant material safety data sheet (MSDS) and (where applicable) the label, listed below.

In accordance with section 20 of the Hazardous Materials Information Review Act, a claimant or any affected party may appeal a decision or order of a screening officer. An affected party may also appeal an undertaking in respect of which a notice has been published in the Canada Gazette. “Affected party” means a person who is not a competitor of the claimant and who uses, supplies or is otherwise involved in the use or supply of the controlled product at a work place, and includes

To initiate the appeal process, a Statement of Appeal (Form 1) as prescribed by the Hazardous Materials Information Review Act Appeal Board Procedures Regulations must be completed and delivered, along with the fee prescribed by section 12 of the Hazardous Materials Information Review Regulations, within 45 days of the publication of this notice in the Canada Gazette, Part I, to the Chief Appeals Officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 4th Floor, Ottawa, Ontario K1A 0K9.

ROSSLYNN MILLER-LEE
Chief Screening Officer

Claimant

Product Identifier (As shown on the MSDS)

Registry Number

Date of Decision

VWR Education Ltd.,
Rochester, New York

WARD-Select

8277

2014-06-30

Reichhold, Inc.,
Research Triangle Park,
North Carolina

UROTUF® F83-M-75

8472

2014-04-29

Afton Chemical Corporation,
Richmond, Virginia

NEMO 1123T

8526

2014-05-23

Fusion, Incorporated,
Willoughby, Ohio

NPA-1070-400

8539

2014-05-23

Momentive Performance Materials,
Markham, Ontario

Silquest® RC-1 silane

8555

2014-04-01

Ashland Inc.,
Dublin, Ohio

PureRad™ 19794 CATIONIC COLD FOIL ADHESIVE

8594

2014-06-19

Momentive Performance Materials,
Markham, Ontario

Niax® silicone L-650

8596

2014-06-17

Champion Technologies Ltd.,
Calgary, Alberta

FlowPlus VR-5004

8649

2014-06-18

MeadWestvaco Corporation -
Specialty Chemicals Division,
North Charleston, South Carolina

EVOTHERM™ H5

8650

2014-04-23

MeadWestvaco Corporation -
Specialty Chemicals Division,
North Charleston, South Carolina

EVOTHERM™ J1

8651

2014-04-23

MeadWestvaco Corporation -
Specialty Chemicals Division,
North Charleston, South Carolina

INDULIN® MQ3

8654

2014-04-23

Chevron Oronite Company LLC,
Bellaire, Texas

OLOA 55501

8670

2014-04-28

Ashland Inc.,
Dublin, Ohio

Purekote™ 23574B HIGH PERFORMANCE PRINT
RECEPTIVE TOPCOAT

8675

2014-06-18

Schlumberger Canada Limited,
Calgary, Alberta

Acid Corrosion Inhibitor A233

8677

2014-04-11

Schlumberger Canada Limited,
Calgary, Alberta

Crosslinker J610

8678

2014-04-16

Schlumberger Canada Limited,
Calgary, Alberta

Emulsion Preventer W063

8679

2014-04-11

Schlumberger Canada Limited,
Calgary, Alberta

Emulsion and Sludge Preventer W064

8680

2014-04-03

3M Canada Company,
London, Ontario

3M™ UV Gloss Clear Coat 9740i

8683

2014-05-20

Calfrac Well Services Ltd.,
Calgary, Alberta

DAP-131

8692

2014-05-08

Calfrac Well Services Ltd.,
Calgary, Alberta

DWP-411

8693

2014-04-28

Ashland Inc.,
Dublin, Ohio

Purekote™ 23574C ULTRA CLEAR PRINT
RECEPTIVE TOPCOAT

8695

2014-06-18

Ashland Inc.,
Dublin, Ohio

Purekote™ 23574D ULTRA CLEAR PRINT
RECEPTIVE TOPCOAT

8696

2014-06-18

Akzo Nobel Surface Chemistry LLC,
Chicago, Illinois

Redicote® E-6100

8707

2014-04-22

Calfrac Well Services Ltd.,
Calgary, Alberta

DWP-955

8715

2014-06-03

Rohm and Haas Canada LP,
West Hill, Ontario

MONOMER QM-1833

8716

2014-06-11

MeadWestvaco Corporation -
Specialty Chemicals Division,
North Charleston, South Carolina

Indulin® 814P

8717

2014-05-21

ClearTech Industries Inc.,
Saskatoon, Saskatchewan

FilterClean A

8732

2014-04-23

ClearTech Industries Inc.,
Saskatoon, Saskatchewan

FilterClean IC

8734

2014-04-24

3M Canada Company,
London, Ontario

3M™ Protective Material PM-2050

8742

2014-04-29

Afton Chemical Corporation,
Richmond, Virginia

TecGARD® 725

8747

2014-06-02

Afton Chemical Corporation,
Richmond, Virginia

TecGARD® 727

8748

2014-06-02

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ AP SOLVENT 800 LFG

8755

2014-04-09

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ AP SOLVENT 806

8756

2014-04-09

Baker Petrolite Corp.,
Sugar Land, Texas

HI-M-PACT™10724 LDHI

8757

2014-04-15

BASF Canada Inc.,
Mississauga, Ontario

Irgacor 843

8759

2014-04-09

Momentive Performance Materials,
Markham, Ontario

Niax® silicone L-5639

8765

2014-06-17

3M Canada Company,
London, Ontario

3M™ SCOTCH-WELD™ STRUCTURAL PLASTIC ADHESIVE 8010, Part B

8770

2014-05-23

Chevron Oronite Company LLC,
Bellaire, Texas

OLOA 59096

8771

2014-04-28

Chevron Oronite Company LLC,
Bellaire, Texas

OLOA 20018

8772

2014-04-28

GE Water & Process Technologies Canada,
Oakville, Ontario

SPEC-AID 8Q5701

8779

2014-06-11

GE Water & Process Technologies Canada,
Oakville, Ontario

SPEC-AID 8Q5550

8780

2014-05-29

GE Water & Process Technologies Canada,
Oakville, Ontario

DUSTREAT DC9138E

8781

2014-05-29

GE Water & Process Technologies Canada,
Oakville, Ontario

FERROQUEST LP7200

8782

2014-05-29

GE Water & Process Technologies Canada,
Oakville, Ontario

FERROQUEST LP7202

8783

2014-05-29

GE Water & Process Technologies Canada,
Oakville, Ontario

LOSALT 53D

8784

2014-05-29

3M Canada Company,
London, Ontario

3M™ SCOTCH-WELD™ EPOXY ADHESIVE EC-2615 B/A (PART A)

8785

2014-04-29

Arclin Canada Ltd.,
Mississauga, Ontario

Arclin HP600 Liquid Phenol Formaldehyde Resin

8787

2014-04-30

Momentive Performance Materials,
Markham, Ontario

Silquest® A-1126 silane

8788

2014-06-23

E.I. du Pont Canada Company,
Mississauga, Ontario

DuPont™ Semi Gloss Sealer & Finish

8798

2014-06-11

E.I. du Pont Canada Company,
Mississauga, Ontario

DuPont™ StoneTech® Professional Semi Gloss Finishing Sealer

8799

2014-06-11

Air Products & Chemicals, Inc.,
Allentown, Pennsylvania

DABCO® BA150 Additive

8806

2014-04-11

Baker Petrolite Corp.,
Sugar Land, Texas

BPR 81476 CORROSION INHIBITOR

8809

2014-04-11

3M Canada Company,
London, Ontario

Scotchkote 6233P 4G, 8G, and 11G Fusion Bonded Epoxy Coating

8810

2014-05-01

Afton Chemical Corporation,
Richmond, Virginia

HiTEC 552G Performance Additive

8811

2014-05-06

Afton Chemical Corporation,
Richmond, Virginia

HiTEC 521F Performance Additive

8812

2014-05-06

BASF Canada Inc.,
Mississauga, Ontario

Inoterra™ EM

8815

2014-04-15

BASF Canada Inc.,
Mississauga, Ontario

Inoterra™ DWE

8816

2014-04-15

Baker Petrolite Corp.,
Sugar Land, Texas

XERIC™ 6005 SOLIDS CONDITIONING AID

8817

2014-04-11

Lubrizol Corporation,
Wickliffe, Ohio

LUBRIZOL® 5056

8820

2014-05-29

Dow Chemical Canada ULC,
Calgary, Alberta

SELEXOL™ Solvent Booster

8821

2014-04-23

Rohm and Haas Canada LP,
West Hill, Ontario

PARALOID CSM-751ER Impact Modifier

8825

2014-05-12

Lubrizol Corporation,
Wickliffe, Ohio

Lubrizol® 9684

8831

2014-05-21

Lubrizol Corporation,
Wickliffe, Ohio

Lubrizol® 9680

8832

2014-05-22

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ LE SOLVENT 703

8836

2014-05-21

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ HS SOLVENT 101

8837

2014-05-06

Dow Chemical Canada ULC,
Calgary, Alberta

XUR201200116-60

8838

2014-05-20

Afton Chemical Corporation,
Richmond, Virginia

HiTEC 2571 Performance Additive

8839

2014-05-02

BASF Canada Inc.,
Mississauga, Ontario

Inoterra™ EMD

8840

2014-04-15

Calfrac Well Services Ltd.,
Calgary, Alberta

DHP-903

8842

2014-06-09

MeadWestvaco Corporation -
Specialty Chemicals Division,
North Charleston, South Carolina

INDULIN® 814D

8844

2014-04-29

Baker Petrolite Corp.,
Sugar Land, Texas

RE8270DMO DEMULSIFIER

8846

2014-06-06

Lonza Inc.,
London, Ontario

Sourban® PW

8848

2014-06-17

Baker Petrolite Corp.,
Sugar Land, Texas

PETROSWEET™ HS03507 H2S SCAVENGER

8849

2014-04-01

Stepan Company,
Northfield, Illinois

PETROSTEP S-3B

8851

2014-04-02

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ NH SOLVENT 602

8853

2014-04-29

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ AP SOLVENT 810

8854

2014-04-29

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ NH SOLVENT 608

8855

2014-04-29

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ AP SOLVENT 814

8856

2014-04-29

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ AP SOLVENT 804

8857

2014-04-29

Air Products & Chemicals, Inc.,
Allentown, Pennsylvania

Ancamide® 702 B75 Curing Agent

8858

2014-04-29

GE Water & Process Technologies Canada,
Oakville, Ontario

EMBREAK 2W2014

8860

2014-04-14

GE Water & Process Technologies Canada,
Oakville, Ontario

PETROFLO 20Y3416

8861

2014-04-14

GE Water & Process Technologies Canada,
Oakville, Ontario

PROSWEET S1761

8862

2014-04-14

GE Water & Process Technologies Canada,
Oakville, Ontario

SPEC-AID 8Q403ULS

8864

2014-04-14

GE Water & Process Technologies Canada,
Oakville, Ontario

THERMOFLO 7031

8865

2014-04-14

Baker Petrolite Corp.,
Sugar Land, Texas

TOLAD™ 3514 ADDITIVE

8866

2014-05-01

Nalco Canada Co.,
Burlington, Ontario

NALCO® DVP6P011

8867

2014-06-16

Nalco Canada Co.,
Burlington, Ontario

NALCO® DVP6P012

8868

2014-06-05

E.I. du Pont Canada Company,
Mississauga, Ontario

DuPont™ Capstone® FS-31

8871

2014-04-30

E.I. du Pont Canada Company,
Mississauga, Ontario

DuPont™ Capstone® CP

8872

2014-04-30

3M Canada Company,
London, Ontario

SCOTCHKOTE 207R Rough Overcoating

8873

2014-05-07

Hydro Technologies (Canada) Inc.,
Québec, Quebec

HY BRITE® DB

8876

2014-04-03

3M Canada Company,
London, Ontario

SCOTCH-WELD™ STRUCTURAL ADHESIVE FILM, AF 163-2

8877

2014-06-06

Engenium Chemicals Corporation,
Calgary, Alberta

OPTIPLUS

8878

2014-04-08

Afton Chemical Corporation,
Richmond, Virginia

HiTEC® 388 Performance Additive

8882

2014-05-21

Afton Chemical Corporation,
Richmond, Virginia

HiTEC® 348 Performance Additive

8883

2014-05-21

Rohm and Haas Canada LP,
West Hill, Ontario

PARALOID™ EXL-2650A Engineering Resin Additive

8888

2014-05-12

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ HS SOLVENT 133

8889

2014-06-09

Dow Chemical Canada ULC,
Calgary, Alberta

UCARSOL™ HS SOLVENT 102

8890

2014-05-27

Dow Chemical Canada ULC,
Calgary, Alberta

TRITON™ DF-20 Surfactant

8891

2014-06-19

GE Water & Process Technologies Canada,
Oakville, Ontario

Losalt LS1512

8892

2014-06-12

GE Water & Process Technologies Canada,
Oakville, Ontario

Losalt LS1521

8894

2014-06-12

Momentive Performance
Materials, Markham, Ontario

Niax® silicone L-878

8899

2014-06-06

PMC ORGANOMETALLIX,
Mount Laurel, New Jersey

THERMOLITE® 178

8906

2014-05-20

E.I. du Pont Canada Company,
Mississauga, Ontario

Capstone® LPA

8922

2014-04-30

Halliburton Energy Services, Inc.,
Mississauga, Ontario

CT-ARMOR

8936

2014-06-19

3M Canada Company,
London, Ontario

3M™ 8805UV Black Piezo Inkjet Ink

8974

2014-05-16

Allnex Canada Inc.,
(c/o Goodmans, LLP),
Paramus, New Jersey

EBECRYL® 8414 radiation curing resins

8991

2014-04-28

Allnex Canada Inc.,
(c/o Goodmans, LLP),
Paramus, New Jersey

EBECRYL® 350 radiation curing resins

8997

2014-06-12

NOTES:

  1. The Notice of Filing published in the Canada Gazette, Part I, on July 30, 2011, listed the subject of the claim bearing Registry Number 8277 to be the chemical identity of three ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity of two ingredients.
  2. The Notice of Filing published in the Canada Gazette, Part I, on April 28, 2012, listed the subject of the claim bearing Registry Number 8555 to be the chemical identity of one ingredient. The subject of the claim on which the screening officer issued the decision is the chemical identity of two ingredients.
  3. The Notice of Filing published in the Canada Gazette, Part I, on June 30, 2012, for the product bearing Registry Number 8594, listed the product identifier to be PURERAD 19794 CAT COLD FOIL ADH. The product identifier for the product on which the screening officer issued the decision was PureRad™ 19794 CATIONIC COLD FOIL ADHESIVE.
  4. The Notice of Filing published in the Canada Gazette, Part I, on June 30, 2012, listed the subject of the claim bearing Registry Number 8596 to be the chemical identity of two ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity of one ingredient.
  5. The Notice of Filing published in the Canada Gazette, Part I, on September 22, 2012, listed the subject of the claim bearing Registry Number 8649 to be the chemical identity of two ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity of one ingredient and the concentration of two ingredients.
  6. The Notice of Filing published in the Canada Gazette, Part I, on September 22, 2012, for the product bearing Registry Number 8675, listed the product identifier to be PUREKOTE 23574B HI PERF PR TC and the subject of the claim to be the chemical identity of four ingredients. The product identifier and the subject of the claim for the product on which the screening officer issued the decision are Purekote™ 23574B HIGH PERFORMANCE PRINT RECEPTIVE TOPCOAT and the chemical identity of three ingredients, respectively.
  7. The Notice of Filing published in the Canada Gazette, Part I, on September 22, 2012, listed the subject of the claim bearing Registry Number 8678 to be the chemical identity of two ingredients and information that could be used to identify a supplier of a controlled product. The subject of the claim on which the screening officer issued the decision is the chemical identity of one ingredient.
  8. The Notice of Filing published in the Canada Gazette, Part I, on September 22, 2012, listed the subject of the claim bearing Registry Number 8679 to be the chemical identity and information that could be used to identify a supplier of a controlled product of three ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity of one ingredient.
  9. The Notice of Filing published in the Canada Gazette, Part I, on September 22, 2012, listed the subject of the claim bearing Registry Number 8693 to be the chemical identity and concentration of three ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity and the concentration of two ingredients.
  10. The Notice of Filing published in the Canada Gazette, Part I, on December 1, 2012, listed the subject of the claim bearing Registry Number 8742 to be the chemical identity of one ingredient. The subject of the claim on which the screening officer issued the decision is the chemical identity of two ingredients.
  11. The Notice of Filing published in the Canada Gazette, Part I, on February 23, 2013, for the product bearing Registry Number 8798, listed the product identifier to be DuPont™ Semi Gloss Sealer and Finisher. The product identifier for the product on which the screening officer issued the decision was DuPont™ Semi Gloss Sealer and Finish.
  12. The Notice of Filing published in the Canada Gazette, Part I, on February 23, 2013, listed the subject of the claim bearing Registry Number 8817 to be the chemical identity and concentration of six ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity of three ingredients and the concentration of six ingredients.
  13. The Notice of Filing published in the Canada Gazette, Part I, on February 23, 2013, listed the subject of the claim bearing Registry Number 8820 to be the chemical identity of five ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity of six ingredients.
  14. The Notice of Filing published in the Canada Gazette, Part I, on February 23, 2013, for the product bearing Registry Number 8825, listed the product identifier to be PARALOID CSM-751ER Impact Modifier and the subject of the claim to be the chemical identity and concentration of one ingredient. The product identifier and the subject of the claim for the product on which the screening officer issued the decision are PARALOID™ CSM-751ER IMPACT MODIFIER and the chemical identity of three ingredients, respectively.
  15. The Notice of Filing published in the Canada Gazette, Part I, on February 23, 2013, listed the subject of the claim bearing Registry Number 8836 to be the chemical identity of three ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity of two ingredients.
  16. The Notice of Filing published in the Canada Gazette, Part I, on February 23, 2013, listed the subject of the claim bearing Registry Number 8844 to be the chemical identity and concentration of six ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity of seven ingredients.
  17. The Notice of Filing published in the Canada Gazette, Part I, on February 23, 2013, listed the subject of the claim bearing Registry Number 8848 to be the chemical identity of three ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity of one ingredient.
  18. The Notice of Filing published in the Canada Gazette, Part I, on September 14, 2013, listed the subject of the claim bearing Registry Number 8853 to be the chemical identity and concentration of two ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity and concentration of one ingredient.
  19. The Notice of Filing published in the Canada Gazette, Part I, on September 14, 2013, listed the subject of the claim bearing Registry Number 8860 to be the chemical identity of two ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity and concentration of three ingredients.
  20. The Notice of Filing published in the Canada Gazette, Part I, on September 14, 2013, listed the subject of the claim bearing Registry Number 8899 to be the chemical identity of one ingredient. The subject of the claim on which the screening officer issued the decision is the chemical identity of two ingredients.
  21. The Notice of Filing published in the Canada Gazette, Part I, on September 14, 2013, listed the subject of the claim bearing Registry Number 8922 to be the chemical identity and concentration of one ingredient. The subject of the claim on which the screening officer issued the decision is the chemical identity of one ingredient.
  22. The Notice of Filing published in the Canada Gazette, Part I, on September 14, 2013, listed the subject of the claim bearing Registry Number 8974 to be the chemical identity and concentration of two ingredients. The subject of the claim on which the screening officer issued the decision is the chemical identity of two ingredients.

There were no written representations from affected parties to the screening officer with respect to any of the above-mentioned claims for exemption and related MSDSs or labels.

Each of the claims for exemption listed above was found to be valid, except for Registry Number 8675 which was found to be partially valid, and Registry Numbers 8277 and 8838 which were found to be invalid. The screening officer reached this decision after reviewing the information in support of the claim, having regard exclusively to the criteria found in section 3 of the Hazardous Materials Information Review Regulations.

With regard to the various data readily available in the literature and any information provided by the claimant, the screening officer found that the respective MSDSs in respect of the claims bearing Registry Numbers 8526, 8670, 8770, 8821, 8832, 8849, 8876, 8890, 8891, 8906, 8936, 8991 and 8997 complied with the applicable requirements of the Hazardous Products Act and the Controlled Products Regulations.

In the case of the claims bearing Registry Numbers 8677, 8678, 8679 and 8680, being claims from an employer with operations in the province of Alberta, the screening officer found that the MSDSs and labels in respect of which the claims were filed did not comply with the applicable disclosure requirements of the Occupational Health and Safety Code 2009 of the Province of Alberta.

In the case of the claim bearing Registry Number 8716, being a claim from an employer with operations in the province of Ontario, the screening officer found that the MSDS in respect of which the claim was filed did not comply with the applicable disclosure requirements of the Occupational Health and Safety Act of the Province of Ontario.

In all cases where the MSDS or the label was determined not to be in compliance with the relevant legislation, the screening officer offered the claimant the possibility of entering into an undertaking whereby the claimant would voluntarily make the changes necessary to bring the MSDS or the label into compliance. Pursuant to subsection 16.1(1) of the Hazardous Materials Information Review Act, the claimant was given 30 days to provide the screening officer with a signed undertaking accompanied by the MSDS or the label amended as necessary.

In the case of the following claims, the claimant supplied the screening officer with a signed undertaking accompanied by the MSDS or label amended as necessary within the time frame specified. The screening officer was satisfied that the claimant had taken the measures set out in the undertaking in the manner and within the period specified therein.

CLAIMS FOR WHICH THE SCREENING OFFICER WAS SATISFIED THAT THE CLAIMANT HAD TAKEN THE MEASURES SET OUT IN THE UNDERTAKING

Pursuant to paragraph 18(1)(b) of the Hazardous Materials Information Review Act, the Chief Screening Officer of the Workplace Hazardous Materials Bureau hereby gives notice of information that has been disclosed on the relevant MSDS or label in compliance with an undertaking.

Registry Number 8472

Date of notice confirming acceptance: May 22, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS and label for skin contact, disclose an approximate flush time of 15 to 20 minutes.
  2. Add “oxides of nitrogen” to the list of hazardous decomposition products.
  3. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2B.

Registry Number 8539

Date of notice confirming acceptance: June 10, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an ACGIH TVL–TWA Exposure Limit of 1 mg/m3 (respirable fraction) for the hazardous ingredient “aluminum”.
  2. Disclose an LD50 (oral, rat) value of 3 160 mg/kg for the confidential hazardous ingredient “silicon”.

Registry Number 8555

Date of notice confirming acceptance: April 22, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose ingestion and inhalation as a route of entry.
  2. Disclose the generic chemical identity and percent concentration for the confidential hazardous ingredient “alkoxy endblocked polysiloxane” in the controlled product in an acceptable manner.
  3. Disclose an ACGIH TVL–STEL Exposure Limit of 1 000 ppm for the hazardous ingredient “ethanol”.
  4. Disclose that the hazardous ingredient “ethanol” has been classified as a suspected human carcinogen (A3) by the ACGIH.
  5. Disclose an LD50 (oral, rat) value of 10 470 mg/kg for the hazardous ingredient “ethanol”.
  6. Disclose an LC50 (vapour, male rat, 4 hours) value of 117 mg/L for the hazardous ingredient “ethanol”.
  7. Disclose that chronic ingestion of the hazardous ingredient “ethanol” in the controlled product has been shown to cause impairment of the male reproductive functions in laboratory animals.
  8. Disclose that the hazardous ingredient “ethanol” in the controlled product reacts synergistically with “n-butyraldoxime” to induce hastened drowsiness, shortness of breath and palpitations.

Registry Number 8596

Date of notice confirming acceptance: July 15, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give two to four glasses of water to drink.

Registry Number 8649

Date of notice confirming acceptance: September 5, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 15 to 20 minutes.
  2. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give small quantities of water to drink.
  3. Add “oxides of nitrogen” to the list of hazardous combustion products.

Registry Number 8650

Date of notice confirming acceptance: June 26, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS.

Registry Number 8651

Date of notice confirming acceptance: June 26, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye and skin contact, disclose an approximate flush time of 30 minutes.
  2. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: should vomiting occur naturally, have the casualty lie on their side, in the recovery position, in order to reduce the risk of aspiration.

Registry Number 8654

Date of notice confirming acceptance: June 26, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS.

Registry Number 8677

Date of notice confirming acceptance: August 21, 2014

The claimant had been advised to amend the MSDS and the label as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes D1A and D2B.
  2. Disclose on the MSDS the chemical identity, CAS registry number and percent concentration for the hazardous ingredient “trimethylpropane ethoxylated, propoxylated” in the controlled product in an acceptable manner.
  3. In relation to the first aid information shown on the MSDS for ingestion and inhalation, disclose a statement to the effect that trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  4. Disclose the AIHA WEEL–TWA Exposure Limit value of 0.2 ppm with a skin notation for the confidential hazardous ingredient “alkyl thiol”.
  5. Disclose an LC50 (vapour, male rat, 4 hours) value of 7.4 mg/L for the hazardous ingredient “formic acid”.
  6. Disclose an LD50 (oral, rat) value of 1 600 mg/kg for the confidential hazardous ingredient “aromatic aldehyde”.
  7. Disclose that acute ingestion of an ingredient in the controlled product has been shown to cause cardiovascular effects in humans.
  8. Disclose that the confidential hazardous ingredient “alkyl thiol” in the controlled product has been shown to cause skin sensitization in laboratory animals.
  9. Disclose on the label that an ingredient in the controlled product has been shown to cause central nervous system (CNS) effects and fatal injury to lungs via aspiration, in laboratory animals.
  10. Disclose on the label that personal protective equipment must be worn for safe handling of the product.
  11. In relation to the first aid information shown on the label for ingestion, disclose a statement to the effect that trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  12. In relation to the first aid information shown on the label for inhalation, disclose a statement to the effect that trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.

Registry Number 8678

Date of notice confirming acceptance: May 29, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS and label as indicated below.

  1. Disclose on the MSDS ingestion as a route of entry.
  2. Disclose the WHMIS D1 pictogram on the label and also on the MSDS, if WHMIS pictograms are shown on the MSDS.
  3. Disclose on the MSDS the presence of an additional confidential hazardous ingredient in the controlled product together with its percent concentration in an acceptable manner.
  4. Disclose on the MSDS the percent concentration for the hazardous ingredient “potassium hydroxide” in the controlled product in an acceptable manner.
  5. Disclose on the MSDS that an ingredient in the controlled product is incompatible with “potassium peroxodisulfate”.
  6. Disclose on the label a statement to the effect that product was toxic by ingestion.
  7. Disclose on the label a statement to the effect that product should not be ingested.
  8. Disclose on the label that personal protective equipment must be worn for safe handling of the product.

Registry Number 8679

Date of notice confirming acceptance: May 22, 2014

The claimant had been advised to amend the MSDS and label as indicated below.

  1. Disclose on the MSDS the chemical identity, CAS registry number and percent concentration for the hazardous ingredient “cross linked PO/EO polymer” in the controlled product in an acceptable manner.
  2. In relation to the first aid information shown on the MSDS for ingestion, disclose a statement to the effect that trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  3. Add “oxides of sulphur” and “hydrogen chloride” to the list of hazardous decomposition products on the MSDS.
  4. Disclose a statement on the MSDS to the effect that the product should be stored in a cool location away from any ignition sources.
  5. Disclose a statement on the label to the effect that a hazardous ingredient in the controlled product has been shown to cause central nervous system (CNS) effects and fatal injury to lungs via aspiration.
  6. Disclose on the label that personal protective equipment must be worn for safe handling of the product.
  7. In relation to the first aid information shown on the MSDS for ingestion, disclose a statement to the effect that trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.

Registry Number 8683

Date of notice confirming acceptance: June 6, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the percent concentration for four hazardous ingredients in the controlled product in an acceptable manner.
  2. In relation to the first aid information shown on the MSDS for skin contact, disclose an approximate flush time of 20 minutes.
  3. Add “oxides of nitrogen” to the list of hazardous combustion products.
  4. Disclose an LD50 (oral, female rat) value of 1 732 mg/kg for the hazardous ingredient “vinyl caprolactam”.
  5. Disclose an LD50 (oral, rat) value of 5.66 g/kg and an LD50 (dermal, rabbit) value of 8.48 mL/kg for the hazardous ingredient “2-ethylhexyl acrylate”.
  6. Disclose that an ingredient in the controlled product has been shown to cause mutagenic effects, in vitro.

Registry Number 8692

Date of notice confirming acceptance: May 30, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye and skin contact, disclose an approximate flush time of 30 minutes.
  2. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: should vomiting occur naturally, have the casualty lie on their side, in the recovery position, in order to reduce the risk of aspiration and that medical attention must be obtained immediately.
  3. Disclose an LD50 (oral, rat) value of 1 875 mg/kg for the controlled product.
  4. Disclose an LD50 (dermal, rabbit) value of 6 280 mg/kg for the hazardous ingredient “2-propanol”.
  5. Disclose that exposure to a hazardous ingredient in the controlled product has been shown to cause teratogenic effects in the presence of maternal toxicity in laboratory animals.
  6. If the WHMIS classification and pictograms are shown on the MSDS, disclose that the controlled product is also in class D1A with pictogram D1.

Registry Number 8693

Date of notice confirming acceptance: May 20, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 15 to 20 minutes.
  2. In relation to the first aid information shown on the MSDS for ingestion, disclose a statement to the effect that trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  3. Disclose an LD50 (dermal, rabbit) value of 6 280 mg/kg for the hazardous ingredient “2-propanol”.
  4. Disclose that exposure to a hazardous ingredient in the controlled product has been shown to cause teratogenic effects in the presence of maternal toxicity in laboratory animals.
  5. If the WHMIS classification and pictograms are shown on the MSDS, disclose that the controlled product is also in class D1B with pictogram D1.

Registry Number 8715

Date of notice confirming acceptance: June 12, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye and skin contact, disclose an approximate flush time of 15 to 20 minutes.
  2. Disclose that exposure to a confidential hazardous ingredient in the controlled product has been shown to cause teratogenic effects in the presence of maternal toxicity in laboratory animals.

Registry Number 8716

Date of notice confirming acceptance: July 3, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose an LC50 (aerosol, rat, 4 hours) value of 7.1 mg/L for the hazardous ingredient “2-methylacrylic acid”.

Registry Number 8717

Date of notice confirming acceptance: June 24, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye and skin contact, disclose an approximate flush time of 30 minutes.
  2. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: should vomiting occur naturally, have casualty lean forward in order to reduce the risk of aspiration.
  3. Disclose an LD50 (oral, rat) value and an LD50 (dermal, rabbit) value for the confidential hazardous ingredient “glycol monoalkyl ether” in an acceptable manner.

Registry Number 8732

Date of notice confirming acceptance: May 22, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 30 minutes.
  2. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give plenty of water to drink.
  3. Disclose that a confidential hazardous ingredient in the controlled product has been shown to cause eye corrosion.
  4. Disclose that a confidential hazardous ingredient in the controlled product has been shown to cause mutagenic effects, in vitro.

Registry Number 8734

Date of notice confirming acceptance: May 22, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 30 minutes.
  2. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give plenty of water to drink.
  3. Disclose an LD50 (oral, mouse) value for the confidential hazardous ingredient “acid B” in an acceptable manner.
  4. Disclose that a confidential hazardous ingredient in the controlled product has been shown to cause teratogenic effects in laboratory animals.

Registry Number 8742

Date of notice confirming acceptance: May 27, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential hazardous ingredient in the controlled product in an acceptable manner.
  2. Add “oxides of nitrogen” to the list of hazardous combustion products.

Registry Number 8747

Date of notice confirming acceptance: June 26, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional hazardous ingredient in the controlled product together with its chemical identity, percent concentration and CAS registry number in an acceptable manner.
  2. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give one glass of water to drink.

Registry Numbers 8755 and 8756

Date of notice confirming acceptance: May 27, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an ACGIH TLV–TWA Exposure Limit for an additional confidential hazardous ingredient in the controlled product in an acceptable manner.
  2. Disclose an LD50 (oral, rat) value for the controlled product in an acceptable manner.
  3. Disclose an LD50 (dermal, rabbit) value for the controlled product in an acceptable manner.

Registry Number 8757

Date of notice confirming acceptance: May 6, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Add “hydrogen chloride” to the list of hazardous decomposition products.

Registry Number 8759

Date of notice confirming acceptance: April 28, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Add “oxides of carbon” to the list of hazardous decomposition products.

Registry Number 8765

Date of notice confirming acceptance: July 15, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose inhalation as a route of entry.
  2. Disclose the presence of an additional confidential hazardous ingredient in the controlled product together with its percent concentration in an acceptable manner.
  3. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give two to four glasses of water to drink.
  4. Disclose that inhalation of an ingredient in the controlled product has been shown to cause reproductive toxicity effects in laboratory animals.

Registry Numbers 8771 and 8772

Date of notice confirming acceptance: May 20, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS.

Registry Number 8779

Date of notice confirming acceptance: July 3, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose that ingestion of a hazardous ingredient in the controlled product has been shown to cause central nervous system (CNS) effects, kidney effects, neurological impairment and death in humans.
  2. Disclose that ingestion of a hazardous ingredient in the controlled product has been shown to cause liver effects in laboratory animals.
  3. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give 2-8 fluid ounces of milk or water.
  4. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: should vomiting occur naturally, have the casualty lie on their side, in the recovery position, in order to reduce the risk of aspiration and trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  5. Add “oxides of carbon” to the list of hazardous decomposition products.
  6. Disclose that an ingredient in the controlled product has been shown to cause teratogenic effects in the absence of maternal toxicity in laboratory animals.
  7. Disclose that ingestion of an ingredient in the controlled product has been shown to cause acute toxicity in humans.
  8. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes D1B and D2A.

Registry Number 8780

Date of notice confirming acceptance: June 27, 2014

The claimant had been advised to amend certain aspects of the content and wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give 2-8 fluid ounces of milk or water.

Registry Number 8781

Date of notice confirming acceptance: June 26, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient in the controlled product can be corrosive to the eyes.
  2. Disclose an LD50 (oral, rat) value for the confidential hazardous ingredient “linear alkyl sulfonate” in an acceptable manner.
  3. In relation to the first aid information shown on the MSDS for skin contact, disclose an approximate flush time of 15 to 20 minutes.
  4. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 30 minutes.
  5. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give 2-8 fluid ounces of milk or water.

Registry Number 8782

Date of notice confirming acceptance: July 2, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose that the controlled product can be corrosive to the eyes and skin.
  2. Disclose that an ingredient in the controlled product can be corrosive to the eyes.
  3. In relation to the first aid information shown on the MSDS for skin contact, disclose an approximate flush time of 30 minutes and that medical attention must be obtained immediately.
  4. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 30 minutes.
  5. Disclose that an ingredient in the controlled product has been shown to cause mutagenic effects, in vitro.
  6. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class E.

Registry Number 8783

Date of notice confirming acceptance: June 24, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient in the controlled product can be corrosive to the eyes.

Registry Number 8784

Date of notice confirming acceptance: June 19, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

Registry Number 8785

Date of notice confirming acceptance: May 16, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Add “oxides of sulphur” and “hydrogen chloride” to the list of hazardous combustion products.

Registry Number 8787

Date of notice confirming acceptance: June 19, 2014

The claimant had been advised to amend certain aspects of the format and wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of two additional hazardous ingredients in the controlled product together with their percent concentration and CAS registry number in an acceptable manner.
  2. Disclose an LD50 (oral, rat) value of 2 900 mg/kg for the hazardous ingredient “phenol-formaldehyde polymer”.
  3. Disclose that the hazardous ingredient “phenol-formaldehyde polymer” in the controlled product has been shown to cause skin sensitization in humans.
  4. Disclose an ACGIH TLV–TWA Exposure Limit of 2 mg/m3 and an ACGIH TLV–STEL Exposure Limit of 6 mg/m3 with inhalable notation for the hazardous ingredient “borax decahydrate”.
  5. Disclose that an ingredient in the controlled product has been shown to cause adverse reproductive and teratogenic effects in the absence of maternal toxicity in laboratory animals.
  6. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 60 minutes.
  7. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: should vomiting occur naturally, have the casualty lie on their side, in the recovery position, in order to reduce the risk of aspiration, and remove the statement to give 240 mL of milk or water.
  8. In relation to the first aid information shown on the MSDS for skin contact, disclose an approximate flush time of 60 minutes and that medical attention must be obtained immediately.

Registry Number 8788

Date of notice confirming acceptance: July 15, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose inhalation as a route of entry.
  2. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: that medical attention must be obtained immediately.
  3. Disclose an LD50 (dermal, rabbit) value for the controlled product, in an acceptable manner.
  4. Disclose that the hazardous ingredient “1,2-ethylenediamine” in the controlled product has been shown to cause respiratory sensitization and development of asthma-like symptoms.

Registry Numbers 8798 and 8799

Date of notice confirming acceptance: June 23, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose the WHMIS acceptable concentration for two confidential hazardous ingredients in the controlled product.

Registry Number 8806

Date of notice confirming acceptance: June 18, 2014

The claimant had been advised to amend certain aspects of the content and wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient in the controlled product has been shown to cause eye corrosion.
  2. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 30 minutes and that medical attention must be obtained immediately.
  3. Disclose an LD50 (dermal, rabbit) value of 260 mg/kg for the hazardous ingredient “tetramethyliminobispropylamine”.
  4. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

Registry Number 8809

Date of notice confirming acceptance: May 6, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose ingestion as a route of entry.
  2. Add “hydrogen chloride” to the list of hazardous combustion products.

Registry Number 8810

Date of notice confirming acceptance: June 19, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 15 to 20 minutes.
  2. Add “hydrogen chloride” to the list of hazardous combustion products.
  3. Disclose that hazardous ingredients in the controlled product have been shown to cause respiratory sensitization in humans.
  4. Disclose that an ingredient in the controlled product has been shown to cause mutagenic effects, in vitro.

Registry Number 8815

Date of notice confirming acceptance: June 5, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 30 minutes.
  2. Disclose an LD50 (dermal, rabbit) value for the confidential hazardous ingredient “alcohols, alkyl, alkoxylated” in an acceptable manner.

Registry Number 8816

Date of notice confirming acceptance: May 22, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 30 minutes.

Registry Number 8817

Date of notice confirming acceptance: May 6, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose ingestion as a route of entry.

Registry Number 8820

Date of notice confirming acceptance: August 26, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes B3, D1B and D2B.
  2. Disclose the presence of an additional hazardous ingredient in the controlled product together with its percent concentration in an acceptable manner.
  3. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: if the casualty is rapidly losing consciousness, is convulsing or is unconscious, vomiting should not be induced and fluids should not be offered to drink.
  4. Disclose an LD50 (oral, rat) value for the confidential hazardous ingredient “olefin sulfide” in an acceptable manner.
  5. Disclose an LD50 (oral, rat) value for the confidential hazardous ingredient “substituted triazole” in an acceptable manner.
  6. Disclose that an ingredient in the controlled product is a skin irritant.
  7. Disclose an LC50 (aerosol, rat, 4 hours) value for the confidential hazardous ingredient “mineral oil” in an acceptable manner.
  8. Disclose that the confidential hazardous ingredient “olefin sulfide” in the controlled product has been shown to cause skin sensitization in laboratory animals.
  9. Disclose that an ingredient in the controlled product has been shown to cause mutagenic effects, in vitro.

Registry Number 8825

Date of notice confirming acceptance: June 16, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional hazardous ingredient in the controlled product together with its chemical identity, percent concentration and CAS registry number, in an acceptable manner.

Registry Number 8831

Date of notice confirming acceptance: July 14, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (dermal, rabbit) value of 2 mL/kg for the hazardous ingredient “dibutylhydrogenphosphite”.

Registry Number 8836

Date of notice confirming acceptance: June 25, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient in the controlled product has been shown to cause teratogenic effects in the absence of maternal toxicity in laboratory animals.
  2. Disclose an LD50 (oral, rat) value for the controlled product in an acceptable manner.
  3. Disclose an LD50 (dermal, rabbit) value for the confidential hazardous ingredients “alkanolamine” and “alkane derivative” in an acceptable manner.

Registry Number 8837

Date of notice confirming acceptance: June 10, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (oral, rat) value for the confidential hazardous ingredient “alkanolamine(1)” in an acceptable manner.

Registry Number 8839

Date of notice confirming acceptance: June 2, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. sIn relation to the first aid information shown on the MSDS for ingestion, remove the statement to give one glass of water to drink.

Registry Number 8840

Date of notice confirming acceptance: May 27, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose a WHMIS acceptable concentration for a confidential hazardous ingredient in the controlled product.
  2. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 30 minutes.

Registry Number 8842

Date of notice confirming acceptance: June 19, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye and skin contact, disclose an approximate flush time of 15 to 20 minutes.
  2. Disclose a lower LD50 (oral, rat) value of 2 040 mg/kg for the hazardous ingredient “2-ethylhexanol”.
  3. Disclose that an ingredient in the controlled product has been shown to cause mutagenic effects in mammalian somatic cells, in vivo.
  4. Disclose that ingestion of an ingredient in the controlled product has been shown to cause teratogenic and embryotoxic effects in the presence of maternal toxicity in laboratory animals.

Registry Number 8844

Date of notice confirming acceptance: June 19, 2014

The claimant had been advised to amend certain aspects of the content and wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional hazardous ingredient in the controlled product together with its chemical identity, percent concentration and CAS registry number in an acceptable manner.
  2. Disclose an LD50 (oral, rat) value for the hazardous ingredient “alkyl amine derivative-3” in an acceptable manner.
  3. Disclose an LD50 (dermal, rabbit) value for the hazardous ingredients “alkyl amine derivative-1” and “alkyl amine derivative-4” in an acceptable manner.
  4. Disclose that an ingredient in the controlled product has been shown to cause mutagenic effects, in vitro.

Registry Number 8846

Date of notice confirming acceptance: June 24, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose that acute dermal exposure to an ingredient in the controlled product has been shown to cause central nervous system (CNS) effects in laboratory animals.

Registry Number 8848

Date of notice confirming acceptance: August 29, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS.

Registry Number 8851

Date of notice confirming acceptance: April 22, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. sIn relation to the first aid information shown on the MSDS for skin contact, disclose an approximate flush time of 15 to 20 minutes.
  2. Disclose that a hazardous ingredient in the controlled product has been classified as a suspected animal carcinogen (A3) by the ACGIH.
  3. Disclose an LD50 (oral, rat) value of 530 mg/kg, an LC50 (vapour, rat, 4 hours) value of 450 ppm and an LD50 (dermal, rabbit) value of 400 mg/kg for the hazardous ingredient “2-butoxyethanol”.
  4. Disclose that ingestion of an ingredient in the controlled product has been shown to cause fetotoxic effects in the presence of maternal toxicity in laboratory animals.
  5. Disclose that acute and repeated oral, dermal and inhalation exposure to an ingredient in the controlled product have been shown to cause red blood cell hemolysis in laboratory animals.
  6. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in classes D1A and D2B.

Registry Number 8853

Date of notice confirming acceptance: June 5, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (oral, rat) and an LD50 (dermal, rabbit) value for the controlled product in an acceptable manner.

Registry Number 8854

Date of notice confirming acceptance: June 5, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient in the controlled product can be corrosive to the eyes.
  2. Disclose an LD50 (oral, rat) and an LD50 (dermal, rabbit) value for the controlled product in an acceptable manner.

Registry Numbers 8855, 8856 and 8857

Date of notice confirming acceptance: June 5, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (oral, rat) and an LD50 (dermal, rabbit) value for the controlled product in an acceptable manner.

Registry Number 8858

Date of notice confirming acceptance: June 5, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose that ingestion of an ingredient in the controlled product has been shown to cause central nervous system (CNS) effects in laboratory animals and humans.
  2. Add “hydrogen chloride” to the list of hazardous decomposition products.
  3. Disclose that an ingredient in the controlled product has been shown to cause teratogenic/embryotoxic effects in the presence of maternal toxicity in laboratory animals.
  4. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

Registry Number 8860

Date of notice confirming acceptance: May 20, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose that ingredients in the controlled product have been shown to cause skin sensitization in laboratory animals.
  2. Disclose the presence of an additional hazardous ingredient in the controlled product together with its percent concentration in an acceptable manner.
  3. In relation to the first aid information shown on the MSDS for skin contact, disclose an approximate flush time of 15 to 20 minutes.

Registry Number 8861

Date of notice confirming acceptance: May 20, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient in the controlled product has been shown to cause eye corrosion.
  2. Disclose that an ingredient in the controlled product has been shown to cause teratogenic effects in the presence of maternal toxicity in laboratory animals.

Registry Number 8862

Date of notice confirming acceptance: May 20, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (oral, rat) value for the confidential hazardous ingredient “heterocyclic amine” in an acceptable manner.
  2. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: should vomiting occur naturally, have casualty lean forward in order to reduce the risk of aspiration.
  3. Disclose that a hazardous ingredient in the controlled product has been classified as a suspected human carcinogen (A2) by the ACGIH.
  4. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D2A.

Registry Number 8864

Date of notice confirming acceptance: May 20, 2014

The claimant had been advised to amend certain aspects of the content and wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (oral, female rat) value of 272 mg/kg for the hazardous ingredient “N,N-dimethylcyclohexylamine”.
  2. Disclose that ingestion and inhalation of an ingredient in the controlled product have been shown to cause fetotoxic and teratogenic effects in the presence of maternal toxicity in laboratory animals.
  3. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1A.

Registry Number 8865

Date of notice confirming acceptance: May 20, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient in the controlled product has been shown to cause skin corrosion.
  2. In relation to the first aid information shown on the MSDS for eye and skin contact, disclose an approximate flush time of 30 minutes.
  3. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: should vomiting occur naturally, have the casualty lie on their side, in the recovery position, in order to reduce the risk of aspiration and trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  4. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give 2-8 fluid ounces of milk or water.
  5. Disclose that exposure to ingredients in the controlled product has been shown to cause teratogenic and embryotoxic effects in the absence of maternal toxicity in laboratory animals.
  6. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class E.

Registry Number 8866

Date of notice confirming acceptance: May 14, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose ingestion as a route of entry.

Registry Number 8867

Date of notice confirming acceptance: July 15, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Add “oxides of nitrogen” and “oxides of sulphur” to the list of hazardous decomposition products.

Registry Number 8868

Date of notice confirming acceptance: July 9, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Add “oxides of nitrogen” and “oxides of sulphur” to the list of hazardous decomposition products.

Registry Number 8871

Date of notice confirming acceptance: May 14, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS.

Registry Number 8872

Date of notice confirming acceptance: May 14, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Add “oxides of nitrogen” and “oxides of sulphur” to the list of hazardous combustion products.

Registry Number 8873

Date of notice confirming acceptance: June 9, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for eye contact, disclose an approximate flush time of 15 to 20 minutes.
  2. Add “oxides of nitrogen” and “hydrogen chloride” to the list of hazardous combustion products.
  3. Disclose an LD50 (oral, rat) value for the controlled product in an acceptable manner.
  4. Disclose that the hazardous ingredient “Bisphenol A diglycidyl ether-bisphenol A copolymer” in the controlled product has been shown to cause respiratory sensitization in humans.

Registry Number 8877

Date of notice confirming acceptance: July 9, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose that the hazardous ingredients “Diglycidyl ether of bisphenol A” and “Phenol, 4,4-(1-methylethylidene)bis-, polymer with (chloromethyl) oxirane (epoxy resin)” in the controlled product have been shown to cause respiratory sensitization and dermal sensitization in humans.

Registry Number 8878

Date of notice confirming acceptance: April 28, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give 2-3 glasses of water to drink.
  2. Disclose an ACGIH TLV–TWA Exposure Limit of 10 ppm (inhalable fraction and vapour) for the hazardous ingredient “diethylene glycol monobutyl ether”.

Registry Number 8888

Date of notice confirming acceptance: June 16, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS.

Registry Number 8889

Date of notice confirming acceptance: August 19, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (oral, rat) value of >500 mg/kg and an LD50 (dermal, rabbit) value of >1 000 mg/kg for the confidential hazardous ingredient “alkanolamine”.

Registry Number 8892

Date of notice confirming acceptance: July 3, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional hazardous ingredient in the controlled product together with its chemical identity, percent concentration and CAS registry number in an acceptable manner.
  2. In relation to the first aid information shown on the MSDS for skin contact, disclose an approximate flush time of 30 minutes.
  3. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give 2-8 fluid ounces of milk or water.
  4. Disclose that an ingredient in the controlled product has been shown to cause mutagenic effects, in vitro.

Registry Number 8894

Date of notice confirming acceptance: July 2, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose an LD50 (oral, rat) value for the confidential hazardous ingredient “amino alcohol” in an acceptable manner.
  2. In relation to the first aid information shown on the MSDS for skin contact, disclose an approximate flush time of 30 minutes.
  3. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: should vomiting occur naturally, have casualty lean forward in order to reduce the risk of aspiration.
  4. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give 4-10 fluid ounces of milk or water.
  5. Disclose a TWAEV Exposure Limit of 11 mg/m3 and a STEV Exposure Limit of 22 mg/m3 for the confidential hazardous ingredient “amino alcohol”.
  6. Disclose that an ingredient in the controlled product has been shown to cause mutagenic effects, in vitro.

Registry Number 8899

Date of notice confirming acceptance: June 20, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional confidential hazardous ingredient in the controlled product together with its percent concentration in an acceptable manner.
  2. Disclose the percent concentration for a confidential hazardous ingredient in the controlled product in an acceptable manner.

Registry Number 8922

Date of notice confirming acceptance: May 14, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose a statement to the effect that metal containers should be grounded during the transfer of large quantities of the controlled product and that the product should be stored away from ignition sources.
  2. Disclose that the controlled product is an eye irritant.
  3. Disclose an LD50 (oral, female rat) value of 12.2 mL/kg for the hazardous ingredient “n-butyl acetate”.

Registry Number 8974

Date of notice confirming acceptance: June 19, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Add “oxides of nitrogen” to the list of hazardous combustion products.
  2. Disclose an LD50 (oral, male rat) value of 4 350 mg/kg for the hazardous ingredient “isobornyl acrylate”.
  3. Disclose that an ingredient in the controlled product has been shown to cause mutagenic effects in laboratory animals, in vivo.

In the case of the following claims, either the claimant did not supply the screening officer with a signed undertaking or the screening officer was not satisfied that the claimant had taken the measures set out in the undertaking in the manner and within the period specified in it. Pursuant to subsection 17(1) of the Hazardous Materials Information Review Act, the screening officer ordered the claimant to comply with the requirements of the relevant legislation within 30 days from the expiry of the appeal period, except that the information in respect of which the claim for exemption was made does not have to be disclosed, and to provide a copy of the amended MSDS to the screening officer within 30 days of expiry of the appeal period.

CLAIMS FOR WHICH THE SCREENING OFFICER ORDERED THE CLAIMANT TO COMPLY WITH THE APPLICABLE DISCLOSURE REQUIREMENTS

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer of the Workplace Hazardous Materials Bureau hereby gives notice of information that the screening officer ordered to be disclosed on a MSDS or label reviewed by the screening officer.

Registry Number 8594

Date of order: August 18, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose that an ingredient in the controlled product has been shown to cause embryotoxic effects in the presence of maternal toxicity in laboratory animals.
  2. Disclose that an ingredient in the controlled product has been shown to cause mutagenic effects, in vitro.
  3. Add “oxides of sulphur” and “hydrogen chloride” to the list of hazardous decomposition products.
  4. Disclose an LD50 (oral, rat) value for the confidential hazardous ingredient “resin” in an acceptable manner.

Registry Number 8680

Date of order: May 6, 2014

The claimant had been advised to amend certain aspects of the content and wording of the MSDS and label. The claimant had been further advised to amend the MSDS and label as indicated below.

  1. In relation to the first aid information shown on the MSDS and label for skin contact, disclose an approximate flush time of 30 minutes.
  2. Disclose on the label that personal protective equipment must be worn for safe handling of the product.

Registry Number 8695

Date of order: August 18, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional hazardous ingredient in the controlled product together with its percent concentration in an acceptable manner.

Registry Number 8696

Date of order: August 18, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional hazardous ingredient in the controlled product together with its percent concentration in an acceptable manner.

Registry Number 8707

Date of order: May 22, 2014

The claimant had been advised to amend certain aspects of the content and wording of the MSDS.

Registry Number 8811

Date of order: June 9, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the chemical identity of an additional hazardous ingredient, “2,6-di-tert-butylphenol”, in the controlled product together with its percent concentration in an acceptable manner.
  2. Disclose the presence of an additional hazardous ingredient in the controlled product together with its chemical identity and percent concentration in an acceptable manner.
  3. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give one glass of water to drink.
  4. Add “oxides of sulphur” to the list of hazardous decomposition products.

Registry Number 8812

Date of order: June 9, 2014

The claimant had been advised to amend certain aspects of the content and wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the chemical identity of an additional hazardous ingredient, “2,6-di-tert-butylphenol”, in the controlled product together with its percent concentration in an acceptable manner.
  2. Disclose the presence of an additional hazardous ingredient in the controlled product together with its chemical identity and percent concentration in an acceptable manner.
  3. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give one glass of water to drink.
  4. Add “oxides of sulphur” and “oxides of nitrogen” to the list of hazardous decomposition products.
  5. Disclose an ACGIH TLV–TWA Exposure Limit for an additional hazardous ingredient in the controlled product in an acceptable manner.
  6. Disclose an LD50 (oral, rat) value of 3.08 g/kg for the hazardous ingredient “zinc dialkyl dithiophosphate”.
  7. Disclose that an ingredient in the controlled product has been shown to cause teratogenic/embryotoxic effects in the absence of maternal toxicity in laboratory animals.

Registry Number 8882

Date of order: June 24, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional hazardous ingredient in the controlled product together with its chemical identity, percent concentration and CAS registry number in an acceptable manner.
  2. In relation to the first aid information shown on the MSDS for inhalation, disclose a statement to the effect that trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  3. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give one glass of water to drink.
  4. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  5. Disclose an LD50 (oral, rat) value of 1 689 mg/kg for the confidential hazardous ingredient “long-chain alkenyl amine”.
  6. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

Registry Number 8883

Date of order: June 24, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. Disclose the presence of an additional hazardous ingredient in the controlled product together with its chemical identity, percent concentration and CAS registry number in an acceptable manner.
  2. In relation to the first aid information shown on the MSDS for inhalation, disclose a statement to the effect that trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  3. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give one glass of water to drink.
  4. In relation to the first aid information shown on the MSDS for skin contact, disclose a statement to the effect that trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  5. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

For the claim below, the screening officer issued the decision that the claim for exemption was partially valid. The screening officer reached this decision after reviewing the information in support of the claim, having regard exclusively to the criteria found in section 3 of the Hazardous Materials Information Review Regulations.

Registry Number 8675

Date of order: August 18, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose that a hazardous ingredient in the controlled product has been classified as a suspected human carcinogen (A3) by the ACGIH.
  2. Disclose the presence of an additional hazardous ingredient in the controlled product together with its percent concentration and CAS registry number in an acceptable manner.
  3. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give milk or water to drink.

For the claims below, the screening officer issued the decision that the claim for exemption was invalid. The screening officer reached this decision after reviewing the information in support of the claim, having regard exclusively to the criteria found in section 3 of the Hazardous Materials Information Review Regulations.

Pursuant to paragraph 18(1)(b) of the Hazardous Materials Information Review Act, the Chief Screening Officer of the Workplace Hazardous Materials Bureau hereby gives notice of information that has been disclosed on the relevant MSDS or label in compliance with an undertaking.

Registry Number 8838

Date of notice confirming acceptance: October 17, 2014

The claimant had been advised to amend certain aspects of the content of the MSDS.

Registry Number 8277

Date of notice confirming acceptance: October 9, 2014

The claimant had been advised to amend the MSDS as indicated below.

  1. Disclose ingestion as a route of entry.
  2. Disclose that ingestion of ingredients in the controlled product has been shown to cause teratogenic and fetotoxic effects in the absence of maternal toxicity in laboratory animals.
  3. Disclose that ingestion of an ingredient in the controlled product has been shown to cause teratogenic and fetotoxic effects in the presence of maternal toxicity in laboratory animals.
  4. Disclose that inhalation of an ingredient in the controlled product has been shown to cause teratogenic effects in the absence of maternal toxicity in laboratory animals.
  5. Disclose that inhalation of an ingredient in the controlled product has been shown to cause teratogenic and fetotoxic effects in the presence of maternal toxicity in laboratory animals.
  6. Disclose that an ingredient in the controlled product has been shown to cause synergistic effects with “N-butyraldoxime” causing drowsiness, shortness of breath and palpitations in humans.
  7. Disclose the presence of an additional hazardous ingredient in the controlled product together with its percent concentration and CAS registry number in an acceptable manner.
  8. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give plenty of water to drink.
  9. In relation to the first aid information shown on the MSDS for ingestion, disclose advice such as the following: should vomiting occur naturally, have the casualty lie on their side, in the recovery position, in order to reduce the risk of aspiration, and medical attention must be obtained immediately. Trained personnel should immediately administer artificial respiration or cardiopulmonary resuscitation if breathing has stopped or the heart has stopped.
  10. Disclose an ACGIH TVL–TWA Exposure Limit, with a skin notation, for the confidential hazardous ingredient “methyl alcohol” in an acceptable manner.
  11. Disclose that an ingredient in the controlled product has been shown to be acutely toxic in humans.
  12. Disclose an LD50 (oral, rat) value of 10 470 mg/kg and an LC50 (vapour, male rat, 4 hours) value of 117 mg/L for the hazardous ingredient “ethanol”.
  13. Disclose an LC50 (aerosol, female rat, 4 hours) value of 2 410 mg/m3 for the hazardous ingredient “dialdehyde”.
  14. Disclose that the hazardous ingredient “methylisobutyl ketone” has been classified as a Group 2B by the International Agency for Research on Cancer (IARC).
  15. If the WHMIS classifications are stated on the MSDS, disclose that the controlled product is also in class D1B.

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer of the Workplace Hazardous Materials Bureau hereby gives notice of information that the screening officer ordered to be disclosed on an MSDS or label reviewed by the screening officer.

Date of order: June 30, 2014

  1. Disclose the presence of two additional hazardous ingredients in the controlled product together with their percent concentration and CAS registry numbers in an acceptable manner.

The product for the following claim, 8748, was discontinued after the issuance of the statement of decisions but prior to the issuance of either a signed undertaking or signed orders. The screening officer has identified the following instances of non-compliance with the requirements of the relevant legislation.

Registry Number 8748

Date of statement of decision: June 2, 2014

The claimant had been advised to amend certain aspects of the wording of the MSDS. The claimant had been further advised to amend the MSDS as indicated below.

  1. In relation to the first aid information shown on the MSDS for ingestion, remove the statement to give one glass of water to drink.
[5-1-o]

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Filing of claims for exemption

Pursuant to paragraph 12(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer of the Workplace Hazardous Materials Bureau hereby gives notice of the filing of the claims for exemption listed below.

In accordance with subsection 12(2) of the Hazardous Materials Information Review Act, affected parties may make written representations to the screening officer with respect to the claim for exemption and the material safety data sheet to which it relates. “Affected parties” means a person who is not a competitor of the claimant and who uses, supplies or is otherwise involved in the use or supply of the controlled product at a work place, and includes

Written representations respecting a claim for exemption cited in the present notice, or respecting the material safety data sheet or label to which the claim relates, must cite the appropriate registry number, state the reasons and evidence upon which the representations are based and be delivered within 30 days of the date of the publication of this notice in the Canada Gazette, Part I, to the screening officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 4th Floor, Ottawa, Ontario K1A 0K9.

ROSSLYNN MILLER-LEE
Chief Screening Officer

The claims listed below seek exemption from the disclosure of supplier confidential business information in respect of a controlled product; such disclosure would otherwise be required under the provisions of the Hazardous Products Act.

Claimant

Product Identifier (As shown on the MSDS)

Subject of the Claim for Exemption

Registry Number

Halliburton Energy Services, Inc.,
Houston Texas

CL-40™ CROSSLINKER

Chemical identity of one ingredient

9294

Rohm and Haas Canada LP,
West Hill, Ontario

ROMAX™ Activator 1001

Chemical identity and concentration of one ingredient

9295

Champion Technologies Ltd.,
Calgary, Alberta

Flow Plus VR-1100

Chemical identity of two ingredients and concentration of three ingredients

9296

Rohm and Haas Canada LP,
West Hill, Ontario

Paraloid EXL-2690 Powder

Chemical identity of two ingredients

9297

Nalco Canada Co.,
Burlington, Ontario

3D TRASAR® 3DT237

Chemical identity of one ingredient

9298

MeadWestvaco Corp.
Specialty Chemicals Div.,
North Charleston, South Carolina

EnvaWet ™ SCTO

Chemical identity and concentration of three ingredients

9299

Chevron Oronite Company LLC,
Bellaire, Texas

OGA 293HF

Chemical identity of one ingredient

9300

Air Products & Chemicals, Inc.,
Allentown, Pennsylvania

ANCAMINE®2014AS Curing Agent

Chemical identity of two ingredients

9301

Air Products & Chemicals, Inc.,
Allentown, Pennsylvania

SURFYNOL®TG SURFACTANT

Chemical identity of two ingredients

9302

Hydro Technologies (Canada) Inc.,
Québec, Quebec

HY BRITE® RT-3000

Chemical identity and concentration of one ingredient

9303

Chevron Oronite Company LLC,
Bellaire, Texas

MAR 730P

Chemical identity of two ingredients

9304

DuPont Electronic and Communication Technologies-MCM,
Research Triangle Park, North Carolina

7292

Chemical identity of one ingredient

9305

Afton Chemical Corporation,
Richmond, Virginia

NEMO 1126T

Chemical identity of five ingredients

9306

Afton Chemical Corporation,
Richmond, Virginia

HiTEC® 6606T

Chemical identity of five ingredients

9307

Evonik Corporation,
Parsippany, New Jersey

Protectosil® 300 S

Chemical identity and concentration of one ingredient

9308

Afton Chemical Corporation,
Richmond, Virginia

HiTEC® 3491LV Performance Additive

Chemical identity of nine ingredients

9309

Guardian Chemicals Inc.,
Sturgeon County, Alberta

PRESSGUARD HP

Chemical identity and concentration of three ingredients

9310

Chevron Oronite Company LLC,
Bellaire, Texas

OLOA 49828

Chemical identity of one ingredient

9311

Air Products & Chemicals, Inc.,
Allentown, Pennsylvania

ANCAMINE® 2264 Curing Agent

Chemical identity of one ingredient

9312

Canadian Energy Services,
Calgary, Alberta

EnerHIB

Chemical identity of two ingredients

9313

PCT Global LLC,
Santa Barbara, California

ENDUROSHIELD GLASS (US)

Chemical identity of one ingredient

9314

PCT Global LLC,
Santa Barbara, California

ENDUROSHIELD TILES & GROUT (US)

Chemical identity of one ingredient

9315

PCT Global LLC,
Santa Barbara, California

ENDUROSHIELD AUTO GLASS PROFESSIONAL (US)

Chemical identity of one ingredient

9316

PCT Global LLC,
Santa Barbara, California

ENDUROSHIELD STAINLESS STEEL (US)

Chemical identity of one ingredient

9317

Afton Chemical Corporation,
Richmond, Virginia

LUBAD 1797

Chemical identity of five ingredients

9318

STIMWRX Energy Services Ltd.,
Calgary, Alberta

STIMWRX-EH3

Chemical identity and concentration of five ingredients

9319

Baker Petrolite Corp.,
Sugar Land, Texas

PAO2360 PARAFFIN CONTROL

Chemical identity of three ingredients

9320

Air Products & Chemicals, Inc.,
Allentown, Pennsylvania

ANQUAMINE® 401 Curing Agent

Chemical identity of one ingredient

9321

Rohm and Haas Canada LP,
West Hill, Ontario

Paraloid™ KM-X100 PRO Impact Modifier

Chemical identity of five ingredients

9322

Dow Chemical Canada ULC,
Calgary, Alberta

SELEXOL® Solvent

Chemical identity and concentration of two ingredients

9323

Evonik Corporation,
Parsippany, New Jersey

Dynasylan® HYDROSIL 2776

Chemical identity and concentration of one ingredient

9324

Nalco Canada Co.,
Burlington, Ontario

NALSIZE® 7548

Chemical identity of one ingredient

9325

Evonik Corporation,
Parsippany, New Jersey

Protectosil® 300 C

Chemical identity and concentration of one ingredient

9326

Home Hardware Stores Ltd.,
Burford, Ontario

ACTIVOX CLEANER

Chemical identity and concentration of one ingredient

9327

Home Hardware Stores Ltd.,
Burford, Ontario

ACTIVOX ACTIVATOR

Chemical identity and concentration of two ingredients

9328

IPAC Chemicals Ltd.,
Vancouver, British Columbia

Envirobind APS

Chemical identity and concentration of one ingredient

9329

E.I. DuPont Canada Company,
Mississauga, Ontario

DuPont™ Cyrel® Cylosol Component A

Chemical identity of one ingredient

9330

E.I. DuPont Canada Company,
Mississauga, Ontario

DuPont™ Cyrel® Cylosol Component B

Chemical identity of one ingredient

9331

Cambrian Solutions,
Oakville, Ontario

Cambrex XAS

Chemical identity of one ingredient

9332

Diversity Technologies Corp.,
Edmonton, Alberta

CHEM CLEAN GREEN

Chemical identity and concentration of three ingredients

9333

Momentive Performance Materials,
Friendly, West Virginia

Niax silicone L-6705

Chemical identity of one ingredient

9334

Momentive Performance Materials,
Friendly, West Virginia

Y-16251

Chemical identity of two ingredients

9335

Secure Energy Services Inc.,
Calgary, Alberta

SECURE CI-810

Chemical identity of three ingredients

9336

RoMix Inc.,
Colleyville, Texas

Back-Set Molecular Cement Dissolver

Chemical identity and concentration of one ingredient

9337

Trican Well Service Ltd.,
Calgary, Alberta

SS-7

Chemical identity and concentration of two ingredients

9338

Engenium Chemicals Corporation,
Calgary, Alberta

IH-FR-8

Chemical identity and concentration of three ingredients

9339

Engenium Chemicals Corporation,
Calgary, Alberta

IH-FM-8

Chemical identity and concentration of three ingredients

9340

Fusion Technologies Inc.,
Calgary, Alberta

CupBuster-1

Chemical identity and concentration of three ingredients

9341

Afton Chemical Corporation,
Richmond, Virginia

HiTEC 2317

Chemical identity of seven ingredients

9342

BWA Water Additives US LLC,
Tucker, Georgia

Flocon 260

Chemical identity and concentration of three ingredients

9343

Merichem Company,
Houston, Texas

MC-510

Chemical identity of three ingredients

9344

Merichem Company,
Houston, Texas

MC-520

Chemical identity of two ingredients

9345

Merichem Company,
Houston, Texas

MC-530

Chemical identity of two ingredients

9346

Merichem Company,
Houston, Texas

MC-540

Chemical identity of one ingredient

9347

Merichem Company,
Houston, Texas

MC-550

Chemical identity of two ingredients

9348

BYK USA Inc.,
Wallingford, Connecticut

Disperbyk-111

Chemical identity of one ingredient

9349

BYK USA Inc.,
Wallingford, Connecticut

Disperplast-1150

Chemical identity of one ingredient

9350

BYK USA Inc.,
Wallingford, Connecticut

BYK-220 S

Chemical identity of one ingredient

9351

Nalco Canada Co.,
Burlington, Ontario

NALCO® EC1021W

Chemical identity of one ingredient

9352

Nalco Canada Co.,
Burlington, Ontario

ACRYL-EX® EC3085A

Chemical identity of one ingredient

9353

Buckeye International Inc.,
Maryland Heights, Missouri

BUCKEYE BLUE

Chemical identity and concentration of two ingredients

9354

Evonik Corporation,
Parsippany, New Jersey

Protectosil® CHEM-TRETE® BSM 400

Chemical identity and concentration of one ingredient

9355

Evonik Corporation,
Parsippany, New Jersey

Protectosil® CIT

Chemical identity and concentration of one ingredient

9356

Calfrac Well Services Corp.,
Denver, Colorado

DWP-926

Chemical identity and concentration of three ingredients

9357

3M Canada Company,
London, Ontario

3M™ Scotch-Weld™ Structural Plastic Adhesive DP8005, Part B

Chemical identity of two ingredients

9358

3M Canada Company,
London, Ontario

3M™ Scotch-Weld™ Structural Plastic Adhesive 8005, Black, Part B

Chemical identity of two ingredients

9359

CESI Chemical,
Marlow, Oklahoma

MA-844W CnF® Additive

Chemical identity and concentration of two ingredients

9360

3M Canada Company,
London, Ontario

3M™ Scotch-Weld™ Structural Plastic Adhesive DP8005, Black, Part B

Chemical identity of two ingredients

9361

Afton Chemical Corporation,
Richmond, Virginia

HiTEC® 5738 Performance Additive

Chemical identity of one ingredient

9362

Afton Chemical Corporation, Richmond, Virginia

HiTEC® 5739 Performance Additive

Chemical identity of one ingredient

9363

[5-1-o]

DEPARTMENT OF INDUSTRY

BOARDS OF TRADE ACT

MISSION CHAMBER OF COMMERCE

Notice is hereby given that His Excellency the Governor General in Council, by Order in Council dated October 23, 2014, has been pleased to change the name of the MISSION CHAMBER OF COMMERCE to the Mission Regional Chamber of Commerce and to change its boundaries to 287th Street (east) to Morris Valley Road (west) and to the Fraser River (north) [to the north end of Stave Lake] upon petition made therefor under sections 4 and 39 of the Boards of Trade Act.

January 9, 2015

VIRGINIE ETHIER
Director

For the Minister of Industry

[5-1-o]

DEPARTMENT OF INDUSTRY

CANADA CORPORATIONS ACT

Application for surrender of charter

Notice is hereby given that, pursuant to the provisions of subsection 32(2) of the Canada Corporations Act, an application for surrender of charter was received from

File No. Name of Company Received
753717-4 THE LOLA STEIN INSTITUTE FOR LEADERSHIP IN EDUCATION 23/12/2014

January 21, 2015

VIRGINIE ETHIER
Director

For the Minister of Industry

[5-1-o]

NOTICE OF VACANCY

CANADA-NOVA SCOTIA OFFSHORE PETROLEUM BOARD

Chairperson (part-time position)

The governments of Canada and Nova Scotia jointly invite applications from qualified individuals for a six-year appointment as Chairperson of the Canada-Nova Scotia Offshore Petroleum Board (CNSOPB).

The CNSOPB is an independent joint agency of the governments of Canada and Nova Scotia. It is responsible for the regulation of petroleum activities in the Nova Scotia offshore area, including the health and safety of offshore workers, protection of the environment during offshore petroleum activities, management and conservation of offshore petroleum resources, compliance with the provisions of the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation Act and the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation (Nova Scotia) Act that deal with Canada-Nova Scotia employment and industrial benefits, issuance of licences for offshore exploration and development, and resource evaluation, data collection, curation, and distribution.

The Board consists of the Chairperson and 4 part-time members and has a staff of 34 employees. It reports to the Government of Canada and the Government of Nova Scotia through the respective ministers responsible for energy. The principal role of the Chairperson is to oversee development of the strategic direction for the CNSOPB, and to promote the Board’s mission and objectives to the public. Moreover, it is the Chairperson’s responsibility to act as the liaison between the members of the Board and the employees of the CNSOPB, the two governments, and stakeholders.

The successful candidate should possess a degree from a recognized university in a relevant field of study or an acceptable combination of education, job-related training and/or experience.

The ideal candidate would have experience on a board, preferably as a chairperson. He or she would have senior management experience in a private or public sector organization, including human and financial resources experience at the senior executive level, as well as experience in the development of strategies, objectives, plans, and best practices and in corporate governance. The candidate would have experience in dealing with industry, the public sector and non-governmental organizations. Experience in the oil and gas sector is desired. It would be considered an asset to have experience in offshore petroleum activities, as well as in representing Canada or Canadian interests in international fora.

The ideal candidate would have knowledge of the mandate and activities of the CNSOPB, of the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation Act, and of the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation (Nova Scotia) Act. He or she would have knowledge of the roles and responsibilities of a chairperson and the board of directors. The candidate should have knowledge of strategic corporate planning, monitoring and evaluation of corporate performance. Financial literacy and knowledge of the federal and provincial governments’ expectations with regard to accountability and reporting are also sought. The ideal candidate would have knowledge of current and emerging issues related to offshore oil and gas exploration and/or development. Knowledge of the operations and challenges of working with both the federal and provincial governments is also desired.

The ideal candidate would have superior leadership and management skills to enable the Board to accomplish its work effectively. The ability to lead discussions and foster debate among Board members, facilitate consensus and manage conflicts, should they arise, is desirable. He or she would be able to anticipate emerging issues and develop strategies to enable the Board to seize opportunities and solve problems. The candidate should be able to work effectively with senior industry, provincial and federal governments, and non-government officials. Superior communication skills, both written and oral, are sought. The candidate would be a person of sound judgment and integrity. In addition, the ideal candidate would possess high ethical standards, tact, discretion and superior interpersonal skills.

Proficiency in both official languages would be preferred.

The successful candidate must be willing to travel to Halifax, Nova Scotia, for Board and Committee meetings, which occur 12 to 15 times a year. The chosen candidate must also be prepared to travel domestically and internationally to represent the CNSOPB across Canada and abroad.

The governments of Canada and Nova Scotia are committed to building a skilled and diverse workforce reflective of Canadian society and would encourage all qualified candidates to apply.

The selected candidate must comply with the Ethical and Political Activity Guidelines for Public Office Holders. The Guidelines are available on the Governor in Council Appointments Web site, under “Reference Material,” at www.appointments-nominations.gc.ca/index.asp?lang=eng.

The Chairperson of the Board must not, during the term of office of Chairperson, be a federal or provincial public servant. The selected candidate will be subject to conflict of interest guidelines established jointly by the responsible federal minister and the responsible provincial minister and would not be subject to any conflict of interest guidelines established by the federal government. The applicable guidelines are available on the CNSOPB Web site at http://www.cnsopb.ns.ca/pdfs/conflict_of_interest_guidelines.pdf.

This notice has been placed in the Canada Gazette to assist the Governor in Council in identifying qualified candidates for this position. It is not, however, intended to be the sole means of recruitment.

Further details about the organization and its activities can be found on its Web site at http://www.cnsopb.ns.ca.

Interested candidates should forward their curriculum vitae by February 21, 2015, to the Assistant Secretary to the Cabinet (Senior Personnel), Privy Council Office, 59 Sparks Street, 1st Floor, Ottawa, Ontario K1A 0A3, 613-957-5006 (fax), GICA-NGEC@pco-bcp.gc.ca (email).

English and French notices of vacancies will be produced in an alternative format upon request. For further information, please contact GICA-NGEC@pco-bcp.gc.ca.

[5-1-o]

NOTICE OF VACANCY

CANADIAN CENTRE ON SUBSTANCE ABUSE

Chief Executive Officer (full-time position)

Salary range: From $128,800 to $150,700
Location: National Capital Region

Established by an Act of Parliament in 1988, the Canadian Centre on Substance Abuse (CCSA) leads collaborative initiatives among governments, professionals, the business community and non-governmental organizations to achieve a national consensus and a collective impact on issues relating to prevention and treatment of substance abuse in Canada, as well as enforcement of legislation in this field.

The Chief Executive Officer (CEO) is accountable for the implementation of the Canadian Centre on Substance Abuse Act, and leads the organization to conceive, build and sustain pan-Canadian strategies aimed at preventing substance abuse and reducing its impact. The CEO must build support and engagement among a wide variety of governments, professional and regulatory institutions, and the not-for-profit and private sectors. Further, the incoming CEO will be required to build on the CCSA’s advanced social innovation practices in a complex area involving health, public safety and social domains.

The ideal candidate would possess a degree from a recognized university in a health-related field, or an acceptable combination of equivalent education, training and/or job-related experience. A post-graduate degree in a health-related field and/or in business administration would be considered an asset.

The ideal candidate would possess management experience at the senior executive level, including managing human and financial resources. Experience in strategic management and in the implementation of modern corporate governance principles and best practices is desired. He or she would have significant experience in the field of substance abuse and/or addictions and/or the health sector. The candidate should have experience in dealing with several levels of government, preferably with senior officials, including the preparation of submissions for funding. Experience leading a variety of consultative and collaborative efforts among diverse groups of stakeholders, including all levels of government, professionals and professional organizations, non-governmental organizations, the business community and the public, is sought.

The ideal candidate would be knowledgeable about the mandate and activities of the CCSA, as well as the legislative framework within which it operates. Knowledge and understanding of sound business practices and principles and risk management is desired. The candidate would have knowledge of the alcohol and drug field, including, but not limited to, prevention, treatment, enforcement and recovery, in terms of policy, practice and application at the national and international level as relevant to the Canadian Centre on Substance Abuse Act. He or she should have knowledge and understanding of the health care system and how it interrelates with substance abuse issues, as well as a broad understanding of the many domains of science related to addictions issues.

The ideal candidate would have the ability to effectively lead an organization into the future and to work with a board of directors in the development of strategies, plans and objectives, as well as the ability to build and maintain effective stakeholder relationships, and to lead diverse groups in order to develop consensus-built strategies and achieve short-, medium- and long-term results. The ability to provide national and international leadership in the field of substance abuse is sought. The candidate should also have the ability to lead high performance teams and motivate them to achieve corporate objectives. He or she would have superior communication skills, both oral and written, and the ability to manage communications with a variety of stakeholders and the media.

To achieve the CCSA’s objectives and carry out its mandate, the CEO would be a strategic and innovative leader who would possesses superior interpersonal skills, tact, diplomacy, and flexibility, and be a person of high ethical standards and integrity. The chosen candidate would also demonstrate sound judgment, impartiality and discretion.

Proficiency in both official languages would be preferred.

The successful candidate must reside in or be willing to relocate to the National Capital Region, or to a location within reasonable commuting distance. The successful candidate must also be willing to travel extensively within Canada and internationally.

The Government is committed to ensuring that its appointments are representative of Canada’s regions and official languages, as well as of women, Aboriginal peoples, disabled persons and visible minorities.

The selected candidate must comply with the Ethical and Political Activity Guidelines for Public Office Holders. The Guidelines are available on the Governor in Council Appointments Web site, under “Reference Material,” at www.appointments-nominations.gc.ca/index.asp?lang=eng.

The selected candidate will be subject to the Conflict of Interest Act. Public office holders appointed on a full-time basis must submit to the Office of the Conflict of Interest and Ethics Commissioner, within 60 days of appointment, a confidential report in which they disclose all of their assets, liabilities and outside activities. For more information, please visit the Office of the Conflict of Interest and Ethics Commissioner’s Web site at http://ciec-ccie.gc.ca/Default.aspx?pid=1&lang=en.

This notice has been placed in the Canada Gazette to assist the Governor in Council in identifying qualified candidates for this position. It is not, however, intended to be the sole means of recruitment.

Further details about the organization and its activities can be found on its Web site at http://www.ccsa.ca/eng/pages/default.aspx.

Interested candidates should forward their curriculum vitae by February 28, 2015, to the Assistant Secretary to the Cabinet (Senior Personnel), Privy Council Office, 59 Sparks Street, 1st Floor, Ottawa, Ontario K1A 0A3, 613-957-5006 (fax), GICA-NGEC@pco-bcp.gc.ca (email).

English and French notices of vacancies will be produced in an alternative format upon request. For further information, please contact GICA-NGEC@pco-bcp.gc.ca.

[5-1-o]

NOTICE OF VACANCIES

NATIONAL ENERGY BOARD

Members (full-time positions)

Salary range: $172,900–$203,300
Location: Calgary, Alberta

The National Energy Board (NEB) is an independent federal tribunal located in Calgary, Alberta. Its mandate is to promote safety and security, environmental protection, and efficient energy infrastructure and markets, and to make decisions in the Canadian public interest within the mandate set by Parliament for the regulation of pipelines, energy development and trade. The NEB has a staff of approximately 400 employees and an annual budget of $71.3 million. It reports to Parliament through the Minister of Natural Resources.

Opportunities exist for full-time Board member positions at the NEB. This recruitment process is being initiated to fill current and future openings.

The NEB consists of not more than nine full-time members, each appointed for a period of seven years. They must reside in or be willing to relocate to a location within reasonable commuting distance of Calgary, Alberta, and must be prepared to travel and work long hours when required. The principal role of Board members is to make independent decisions in the Canadian public interest in the area of energy regulation.

The ideal candidates for these positions would possess a degree from a recognized university in a relevant field of study or an acceptable combination of education, job-related training and/or experience. A degree in economics, engineering, environmental science, finance or law would be considered an asset.

The candidates would have experience in dealing with energy-related economic, engineering, social, safety, environmental or regulatory issues, as well as extensive experience in taking decisions requiring an objective and careful balance of conflicting or contradictory considerations. Experience in the interpretation and application of legislation is sought, and experience in dealing with economic, social, safety, and environmental issues within Aboriginal communities would be considered an asset. Experience in dealing with international energy-related matters would also be considered an asset.

The ideal candidates would possess knowledge of the mandate and activities of the NEB, as well as its legislative framework, including the National Energy Board Act, and the regulatory and business environments within which the NEB operates. Knowledge of the functioning of energy markets and the energy sector (economic, engineering, social, safety and/or environmental components) and of the role of government and regulatory agencies in facilitating market outcomes that are in keeping with the Canadian public interest is sought. The candidates should also be knowledgeable about administrative law, principles of natural justice, and the rules and practices followed by adjudicative tribunals in Canada. Knowledge of the aspirations of Canada’s Aboriginal peoples, their history, and their vision of Canada’s future is desired.

The ideal candidates would be able to analyze significant amounts of complex technical information and make concrete decisions within a time frame bound by legislated time limits and service standards. They should have the ability to think strategically, to frame questions and to conduct analysis with a thorough understanding of the energy sector and related policy issues, and to constructively question and challenge in an appropriate manner. They should also possess superior communication skills, both written and oral, with the ability to write clear and concise reports, analyses and decisions. The candidates would have the ability to reconcile divergent stakeholder positions, taking into account associated economic, social and environmental implications.

The ideal candidates would be respectful, fair and impartial, as well as tactful and discreet. Superior interpersonal skills, sound judgment and collegiality, combined with high ethical standards and integrity, are also desired.

Proficiency in both official languages would be preferred.

Pursuant to the National Energy Board Act, Board members of the NEB must be Canadian citizens or permanent residents within the meaning of the Immigration and Refugee Protection Act. In addition, Board members must not, as owners, shareholders, directors, officers, partners or otherwise, be engaged in the business of producing, selling, buying, transmitting, exporting, importing or otherwise dealing in hydrocarbons or electricity nor hold any bond, debenture or other security of a corporation engaged in any such business. Finally, they must devote the whole of their time to the performance of their duties under this Act, and they shall not accept or hold any office or employment inconsistent with their duties and functions under this Act.

The Government is committed to ensuring that its appointments are representative of Canada’s regions and official languages, as well as of women, Aboriginal peoples, disabled persons and visible minorities.

The selected candidates must comply with the Ethical and Political Activity Guidelines for Public Office Holders. The Guidelines are available on the Governor in Council Appointments Web site, under “Reference Material,” at www.appointments-nominations.gc.ca/index.asp?lang=eng.

The selected candidates will be subject to the Conflict of Interest Act. Public office holders appointed on a full-time basis must submit to the Office of the Conflict of Interest and Ethics Commissioner, within 60 days of appointment, a confidential report in which they disclose all of their assets, liabilities and outside activities. For more information, please visit the Office of the Conflict of Interest and Ethics Commissioner’s Web site at http://ciec-ccie.gc.ca/Default.aspx?pid=1&lang=en.

This notice has been placed in the Canada Gazette to assist the Governor in Council in identifying qualified candidates for these positions. It is not, however, intended to be the sole means of recruitment.

Further details about the organization and its activities can be found on its Web site at www.neb-one.gc.ca.

For more information, please contact Tim Hamilton or Brian Mellor at 403-410-6700 or at calgaryopportunities@boyden.com. To apply for these positions, please visit the Boyden Global Executive Search Web site at www.boyden.ca.

English and French notices of vacancies will be produced in an alternative format upon request. For further information, please contact GICA-NGEC@pco-bcp.gc.ca.

[5-1-o]